- Location
Bayer HealthCare
"-
Thoratec Has Replaced CEO with The Man Who Previously LED The Company for a Decade
Sep 30, 2014Thoratec Corp. has replaced CEO Gary Burbach with the man who previously led the company for a decade. New president and CEO Keith Grossman served in those roles at the Pleasanton, CA–based company from 1996 to 2006, when Burbach ...
-
Bayer HealthCare Has Failed to Win The Backing of The US FDA's Cardiovascular
Jan 20, 2014Bayer HealthCare has failed to win the backing of the US FDA's Cardiovascular and Renal Drugs Advisory Committee to expand the use of its oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily (BID) in combination with standard ...
Tags: FDA Panel, ACS Patients
-
Most-recognized Anti-infective Brand in North America Is Cipro
Dec 23, 2013The most-recognized anti-infective brand in North America is Cipro. The brand was most-recognized by 7 percent of physicians in a survey conducted by Brand Institute Inc. during the second quarter of 2013. Cipro, comprising ciprofloxacin, ...
-
Genzyme Has Obtained an Approval From Health Canada for Its Lemtrada
Dec 17, 2013Genzyme, a Sanofi company, has obtained an approval from Health Canada for its Lemtrada (alemtuzumab) for the treatment of relapsing remitting multiple sclerosis (RRMS). Health Canada has approved Lemtrada for the management of adult ...
-
Versant Ventures Has Established an Office in Vancouver This Year
Dec 11, 2013US-based life sciences venture capital firm Versant Ventures is expanding its operations into Canada in order to invest in early-stage drug discovery programs. The company has established an office in Vancouver this year and created a new ...
Tags: Versant Ventures, Drug Discovery
-
DRGT Has Entered Into a Multi-Year Collaboration Deal with Bayer Healthcare
Dec 10, 2013Druggability Technologies (DRGT) has entered into a multi-year collaboration deal with Bayer HealthCare that will deploy DRGT's proprietary Super-API platform to support Bayer HealthCare's formulation efforts directed at enhancing compound ...
Tags: Drugs Discovery, Bayer Healthcare
-
Bayer HealthCare Has Submitted VEGF Trap-Eye for Regulatory Approval in Japan
Dec 5, 2013Bayer HealthCare has submitted VEGF Trap-Eye (aflibercept solution for injection) for regulatory approval in Japan to treat patients with myopic choroidal neovascularization (myopic CNV), one of the most common causes of eye disease. In ...
-
The FDA Has Approved Nexavar for The Treatment of Locally Recurrent or Metastatic
Nov 26, 2013Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...
-
Bayer and Regeneron Pharmaceuticals Are Collaborating on The Global Development of Eylea
Nov 26, 2013Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Bayer HealthCare's Eylea (aflibercept, solution for intravitreal injection) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). In ...
-
Bayer Healthcare Has Received Marketing Authorization From The European Commission
Nov 19, 2013Bayer HealthCare has received marketing authorization from the European Commission (EC) for its Xofigo injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral ...
-
Bayer HealthCare Has Announced That FDA Has Cleared Its CONTOUR Next Link Bgm System
Oct 23, 2013Bayer HealthCare has announced that the US Food and Drug Administration (FDA) has cleared its CONTOUR next link blood glucose monitoring (BGM) system as a component of Medtronic's new MiniMed 530G with Enlite, a breakthrough diabetes ...
Tags: Bayer HealthCare, Medicine
-
Bayer HealthCare Pharmaceuticals Has Obtained FDA Approval for Its Adempas Tablets
Oct 11, 2013Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained the US Food and Drug Administration (FDA) approval for its Adempas (riociguat) tablets. Adempas tablets are developed for the treatment of adults with ...
-
Bayer HealthCare Pharmaceuticals Has Obtained Two Separate Orphan Drug Designations
Sep 27, 2013Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained two separate orphan drug designations from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its investigational, oral medication ...
Tags: Drug Designations, Medicine
-
EMA Has Received an Application From Bayer HealthCare for Marketing Authorization
Sep 10, 2013The European Medicines Agency (EMA) has received an application from Bayer HealthCare for marketing authorization of its oral multi-kinase inhibitor, regorafenib, for the treatment of patients with gastrointestinal stromal tumors (GlST). ...
-
European Commission Has Approved Regeneron Pharmaceuticals's Eylea Injection
Sep 2, 2013The European Commission has approved Regeneron Pharmaceuticals's Eylea (aflibercept) injection for the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Eylea is a recombinant ...
Tags: fusion protein, Eylea